文献速递临床试验与 GCP基础与转化研究

YH0618颗粒防治乳腺癌化疗性脱发的随机双盲多中心试验方案

The effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial.
PubMed 文献 · Trials · 2019-12-12

本研究为随机、双盲、多中心临床试验,纳入即将开始化疗的乳腺癌患者,比较YH0618颗粒与安慰剂对化疗所致脱发的作用。主要结局为WHO毒性分级II级脱发出现时间及第5周期前毛发质量与毛囊生长指标,并从肾虚或肾功能角度探讨机制。

要点

  • 乳腺癌化疗患者随机接受YH0618颗粒或安慰剂,双盲多中心设计。
  • 主要结局为WHO毒性分级II级脱发出现时间及第5周期前毛发检测指标。
  • YH0618每日2次、每次6 g,每周6天,第1至第4化疗周期服用。

核心结论

  • YH0618颗粒可能促进化疗后毛发生长且不干扰化疗抗肿瘤作用,本试验拟进一步验证其对乳腺癌化疗性脱发的疗效与机制。

研究设计与样本

  • 随机、双盲、多中心临床试验,纳入即将开始化疗的合格乳腺癌患者,随机分为A组(YH0618颗粒)与B组(安慰剂)。
  • 化疗药物含紫杉类或/和蒽环类,方案至少6个周期,每3周1个周期。

主要发现

  • A组YH0618颗粒每日2次、每次6 g,每周6天,以300 ml温水混合,第1至第4化疗周期服用;B组同法服用安慰剂。
  • 主要结局为WHO毒性分级评估的II级脱发出现时间,以及第5化疗周期前毛发与头皮检测仪记录的毛发质量和毛囊生长客观指标。
  • 次要结局包括面色与指甲颜色变化、指甲纵嵴分级、生活质量、疲劳程度、血常规、肝肾功能及反映中医肾虚的医学指标。

关键数值与推荐

  • 主要结局指标为WHO毒性分级量表评估的II级脱发出现时间点。
  • YH0618颗粒用法为每日2次、每次6 g、每周6天,第1至第4化疗周期服用。

临床怎么用

  • 该方案为研究方案,尚不能据此改变临床实践;结果可为乳腺癌化疗性脱发提供潜在干预证据。

局限性

  • 本文为研究方案,尚未报告疗效与安全性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hair loss is one of the most common side effects of chemotherapy, and can cause persistent negative emotions, further affecting therapeutic effects and reducing the quality of life. However, there are no clinically safe and effective methods to solve the problem at present. Our previous clinical and animal studies showed that a medicinal and edible decoction, YH0618, could significantly promote hair growth in cancer patients after chemotherapy, without interfering with the anti-tumor effects of chemotherapy. Besides, the theory of Chinese Medicine believes that the "Essence of the kidney is reflected on the hair". Therefore, this study will further explore the efficacy of YH0618 granule on chemotherapy-induced hair loss in patients with breast cancer by a randomized, double-blind, multi-center clinical trial and elucidate the potential mechanism from the aspect of kidney deficiency or renal dysfunction. METHODS/DESIGN: Eligible breast cancer patients who will start chemotherapy will be randomly divided into group A (YH0618 granule) and group B (placebo). The chemotherapeutic agents contain taxanes or/and anthracyclines, and the chemotherapy regimen will be for at least six cycles with a cycle every 3 weeks. Subjects assigned to group A will receive YH0618 granules twice a day (6 g each time), 6 days a week, mixed with 300 ml warm water from the first to the fourth chemotherapy cycle. Subjects in group B will receive the placebo granule in the same manner. The primary outcome is the time point of occurrence of hair loss reaching grade II as assessed by the WHO Toxicity Grading Scale, and objective indices of hair quality and hair-follicle growth recorded by a hair and scalp detector before the fifth chemotherapy cycle. Secondary outcomes include changes of facial color and thumbnail color, grading of thumbnails ridging, assessment of quality life, level of fatigue, routine blood test results, hepatic and renal function, and certain medical indicators which can reflect kidney deficiency in Chinese Medicine. DISCUSSION: This research is of great significance for the treatment of cancer and improving the quality of life of cancer patients. The study may provide the most direct evidence for meeting clinical needs and lay a solid scientific foundation for later product development. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR1800020107. Registered on 14 December 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. You JS, Guo L, Huang M, et al. The effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial. Trials. 2019. PMID: 31831051. doi:10.1186/s13063-019-3893-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。